BIAF - bioAffinity Technologies, Inc.


0.7
0.017   2.371%

Share volume: 1,901,930
Last Updated: 04-07-2025
Business Services/Services – Research, Development, Testing Labs: 0.01%

PREVIOUS CLOSE
CHG
CHG%

$0.68
0.02
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
18%
Profitability 0%
Dept financing 13%
Liquidity 49%
Performance 30%
Company vs Stock growth
vs
Performance
5 Days
-0.16%
1 Month
93.91%
3 Months
-24.00%
6 Months
-60.00%
1 Year
-73.58%
2 Year
-57.83%
Key data
Stock price
$0.70
P/E Ratio 
0.00
DAY RANGE
$0.56 - $0.77
EPS 
-$0.82
52 WEEK RANGE
$0.24 - $3.16
52 WEEK CHANGE
-$73.18
MARKET CAP 
27.974 M
YIELD 
N/A
SHARES OUTSTANDING 
13.490 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
0.39
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$94,350,140
AVERAGE 30 VOLUME 
$27,285,567
Company detail
CEO: Maria Zannes
Region: US
Website: bioaffinitytech.com
Employees: 10
IPO year: 2022
Issue type: Common Stock
Market: XNAS
Industry: Business Services/Services – Research, Development, Testing Labs
Sector: Services

bioAffinity Technologies, Inc. is a privately held company incorporated in Delaware addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. Our principal executive office is located at 22211 West Interstate 10, Suite 1206, San Antonio, Texas 78257, and our telephone number at that address is (210) 698-5334. Our laboratory diagnostic and therapeutic research is conducted at The Harvey Sandler Cancer Research Laboratories, which is located at Science Research Laboratories, Suite 1.424, University of Texas at San Antonio, San Antonio, Texas.

Recent news
loading